A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a study of the drug perifosine that consists of 2 parts. The first part of this study
was designed to determine the highest dose of perifosine that can be administered to people
every week without severe or prolonged nausea, vomiting and diarrhea. This study started with
patients taking 900 mg/week and went up to 1800 mg/week. Part I of this study is completed.
The MTD had been determined and incorporated in Part II.
The goals in Part II are to:
1. Compare the gastrointestinal toxicity of 3 different dose-schedules and
2. Obtain preliminary information on the response rate of perifosine in non-small cell lung
cancer.